Your browser doesn't support javascript.
loading
GENESIS: a French national resource to study the missing heritability of breast cancer.
Sinilnikova, Olga M; Dondon, Marie-Gabrielle; Eon-Marchais, Séverine; Damiola, Francesca; Barjhoux, Laure; Marcou, Morgane; Verny-Pierre, Carole; Sornin, Valérie; Toulemonde, Lucie; Beauvallet, Juana; Le Gal, Dorothée; Mebirouk, Noura; Belotti, Muriel; Caron, Olivier; Gauthier-Villars, Marion; Coupier, Isabelle; Buecher, Bruno; Lortholary, Alain; Dugast, Catherine; Gesta, Paul; Fricker, Jean-Pierre; Noguès, Catherine; Faivre, Laurence; Luporsi, Elisabeth; Berthet, Pascaline; Delnatte, Capucine; Bonadona, Valérie; Maugard, Christine M; Pujol, Pascal; Lasset, Christine; Longy, Michel; Bignon, Yves-Jean; Adenis, Claude; Venat-Bouvet, Laurence; Demange, Liliane; Dreyfus, Hélène; Frenay, Marc; Gladieff, Laurence; Mortemousque, Isabelle; Audebert-Bellanger, Séverine; Soubrier, Florent; Giraud, Sophie; Lejeune-Dumoulin, Sophie; Chevrier, Annie; Limacher, Jean-Marc; Chiesa, Jean; Fajac, Anne; Floquet, Anne; Eisinger, François; Tinat, Julie.
Afiliación
  • Sinilnikova OM; Cancer Research Centre of Lyon, CNRS UMR5286, Inserm U1052, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France.
  • Dondon MG; Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon, Centre Léon Bérard, Lyon, France.
  • Eon-Marchais S; Inserm, U900, Paris, France. mariegabrielle.dondon@curie.fr.
  • Damiola F; Institut Curie, Paris, France. mariegabrielle.dondon@curie.fr.
  • Barjhoux L; PSL Research University, Paris, France. mariegabrielle.dondon@curie.fr.
  • Marcou M; Mines ParisTech, Fontainebleau, France. mariegabrielle.dondon@curie.fr.
  • Verny-Pierre C; Inserm, U900, Paris, France. severine.eonmarchais@curie.fr.
  • Sornin V; Institut Curie, Paris, France. severine.eonmarchais@curie.fr.
  • Toulemonde L; PSL Research University, Paris, France. severine.eonmarchais@curie.fr.
  • Beauvallet J; Mines ParisTech, Fontainebleau, France. severine.eonmarchais@curie.fr.
  • Le Gal D; Cancer Research Centre of Lyon, CNRS UMR5286, Inserm U1052, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France. francesca.damiola@lyon.unicancer.fr.
  • Mebirouk N; Cancer Research Centre of Lyon, CNRS UMR5286, Inserm U1052, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France. laure.barjhoux@lyon.unicancer.fr.
  • Belotti M; Inserm, U900, Paris, France. morgane.marcou@apr.aphp.fr.
  • Caron O; Institut Curie, Paris, France. morgane.marcou@apr.aphp.fr.
  • Gauthier-Villars M; PSL Research University, Paris, France. morgane.marcou@apr.aphp.fr.
  • Coupier I; Mines ParisTech, Fontainebleau, France. morgane.marcou@apr.aphp.fr.
  • Buecher B; Cancer Research Centre of Lyon, CNRS UMR5286, Inserm U1052, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France. carole.verny@lyon.unicancer.fr.
  • Lortholary A; Cancer Research Centre of Lyon, CNRS UMR5286, Inserm U1052, Université Claude Bernard Lyon 1, Centre Léon Bérard, Lyon, France. valerie.sornin@lyon.unicancer.fr.
  • Dugast C; Inserm, U900, Paris, France. lucietoulemonde@hotmail.com.
  • Gesta P; Institut Curie, Paris, France. lucietoulemonde@hotmail.com.
  • Fricker JP; PSL Research University, Paris, France. lucietoulemonde@hotmail.com.
  • Noguès C; Mines ParisTech, Fontainebleau, France. lucietoulemonde@hotmail.com.
  • Faivre L; Inserm, U900, Paris, France. juana.beauvallet@curie.fr.
  • Luporsi E; Institut Curie, Paris, France. juana.beauvallet@curie.fr.
  • Berthet P; PSL Research University, Paris, France. juana.beauvallet@curie.fr.
  • Delnatte C; Mines ParisTech, Fontainebleau, France. juana.beauvallet@curie.fr.
  • Bonadona V; Inserm, U900, Paris, France. dorothee.legal@curie.fr.
  • Maugard CM; Institut Curie, Paris, France. dorothee.legal@curie.fr.
  • Pujol P; PSL Research University, Paris, France. dorothee.legal@curie.fr.
  • Lasset C; Mines ParisTech, Fontainebleau, France. dorothee.legal@curie.fr.
  • Longy M; Inserm, U900, Paris, France. noura.mebirouk@curie.fr.
  • Bignon YJ; Institut Curie, Paris, France. noura.mebirouk@curie.fr.
  • Adenis C; PSL Research University, Paris, France. noura.mebirouk@curie.fr.
  • Venat-Bouvet L; Mines ParisTech, Fontainebleau, France. noura.mebirouk@curie.fr.
  • Demange L; Institut Curie, Service de Génétique, Paris, France. muriel.belotti@curie.fr.
  • Dreyfus H; Institut de Cancérologie Gustave Roussy, Service d'Oncologie Génétique, Villejuif, France. olivier.caron@gustaveroussy.fr.
  • Frenay M; Institut Curie, Service de Génétique, Paris, France. marion.gauthier-villars@curie.fr.
  • Gladieff L; Hôpital Arnaud de Villeneuve, CHU Montpellier, Service de Génétique médicale et Oncogénétique, Montpellier, France. i-coupier@chu-montpellier.fr.
  • Mortemousque I; ICM Val d'Aurel, Unité d'Oncogénétique, Montpellier, France. i-coupier@chu-montpellier.fr.
  • Audebert-Bellanger S; Institut Curie, Service de Génétique, Paris, France. bruno.buecher@curie.fr.
  • Soubrier F; Centre Catherine de Sienne, Service d'Oncologie Médicale, Nantes, France. lortholary.alain@catherinedesienne.fr.
  • Giraud S; Centre Eugène-Marquis, Service de Génétique, Rennes, France. c.dugast@rennes.unicancer.fr.
  • Lejeune-Dumoulin S; CH Georges Renon, Service Oncogénétique pour la consultation oncogénétique régionale Poitou-Charentes, Niort, France. paul.gesta@ch-niort.fr.
  • Chevrier A; Centre Paul Strauss, Unité d'Oncologie, Strasbourg, France. jfricker@strasbourg.unicancer.fr.
  • Limacher JM; Institut Curie, Hôpital René Huguenin, Saint-Cloud, France. catherine.nogues@curie.fr.
  • Chiesa J; Hôpital d'Enfants, Service de Génétique Médicale, Dijon, France. laurence.faivre@chu-dijon.fr.
  • Fajac A; Centre Georges François Leclerc, Oncogénétique, Dijon, France. laurence.faivre@chu-dijon.fr.
  • Floquet A; ICL Alexis Vautrin, Unité d'Oncogénétique, Vandœuvre-lès-Nancy, France. e.luporsi@nancy.unicancer.fr.
  • Eisinger F; Centre François Baclesse, Unité de pathologie gynécologique, Caen, France. p.berthet@baclesse.fr.
  • Tinat J; Centre René Gauducheau, Unité d'Oncogénétique, Nantes Saint Herblain, France. capucine.delnatte@ico.unicancer.fr.
BMC Cancer ; 16: 13, 2016 Jan 12.
Article en En | MEDLINE | ID: mdl-26758370
ABSTRACT

BACKGROUND:

Less than 20% of familial breast cancer patients who undergo genetic testing for BRCA1 and BRCA2 carry a pathogenic mutation in one of these two genes. The GENESIS (GENE SISter) study was designed to identify new breast cancer susceptibility genes in women attending cancer genetics clinics and with no BRCA1/2 mutation.

METHODS:

The study involved the French national network of family cancer clinics. It was based on enrichment in genetic factors of the recruited population through case selection relying on familial criteria, but also on the consideration of environmental factors and endophenotypes like mammary density or tumor characteristics to assess potential genetic heterogeneity. One of the initial aims of GENESIS was to recruit affected sibpairs. Siblings were eligible when index cases and at least one affected sister were diagnosed with infiltrating mammary or ductal adenocarcinoma, with no BRCA1/2 mutation. In addition, unrelated controls and unaffected sisters were recruited. The enrolment of patients, their relatives and their controls, the collection of the clinical, epidemiological, familial and biological data were centralized by a coordinating center.

RESULTS:

Inclusion of participants started in February 2007 and ended in December 2013. A total of 1721 index cases, 826 affected sisters, 599 unaffected sisters and 1419 controls were included. 98% of participants completed the epidemiological questionnaire, 97% provided a blood sample, and 76% were able to provide mammograms. Index cases were on average 59 years old at inclusion, were born in 1950, and were 49.7 years of age at breast cancer diagnosis. The mean age at diagnosis of affected sisters was slightly higher (51.4 years). The representativeness of the control group was verified.

CONCLUSIONS:

The size of the study, the availability of biological specimens and the clinical data collection together with the detailed and complete epidemiological questionnaire make this a unique national resource for investigation of the missing heritability of breast cancer, by taking into account environmental and life style factors and stratifying data on endophenotypes to decrease genetic heterogeneity.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Mutación de Línea Germinal / Proteínas de Neoplasias Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Mutación de Línea Germinal / Proteínas de Neoplasias Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Francia